Skip to main content
. 2015 May 22;10:64. doi: 10.1186/s13023-015-0280-3

Table 2.

Baseline (pre-treatment) characteristics of 133 treated patients with GD1 by investigative site

Total South Florida Toronto Atlanta Los Angeles Pittsburgh
Patients: N 133 61 25 15 24 8
Patients with splenectomy: n (%) 39 (29.3) 17 (27.9) 8 (32.0) 5 (33.3) 5 (20.8) 4 (50.0)
Women: n (%) 81 (61) 36 (59) 18 (72) 10 (66.7) 11 (45.8) 6 (75)
Ethnicity: n (%)
 Ashkenazi Jewish 68 (51.1) 45 (73.8) 4 (16.0) 3 (20.0) 15 (62.5) 1 (12.5)
 Part Ashkenazi 13 (9.8) 7 (11.5) 1 (4.0) 1 (6.7) 4 (16.7) 0
 Non-Jewish 44 (33.1) 9 (14.8) 19 (76.0) 8 (53.3) 2 (8.3) 6 (75.0)
 Unknown 8 (6.0) 0 1 (4.0) 3 (20.0) 3 (12.5) 1 (12.5)
Age at diagnosis (y)
 Mean (SD) 29.7 (18.8) 34.6 (21.2) 17.0 (19.2) 30.7 (14.1) 32.0 (18.4) 23.4 (19.1)
Age at first treatment (y)
 Mean (SD) 44.5 (18.8 52.2 (16.9) 33.5 (19.3) 37.3 (17.2) 43.1 (16.3) 38.5 (19.0)
Years on treatment
 Mean (SD) 13.3 (6.1) 13.3 (6.0) 12.0 (5.6) 14.3 (6.4) 12.8 (6.8) 17.0 (4.6)
Current age (y)
 Mean (SD) 57.8 (18.4) 65.5 (15.5) 45.5 (18.9) 51.6 (18.8) 55.9 (16.5) 55.5 (19.2)
Genotype: N (%)
 N370S/N370S 52 (39.1) 35 (57.4) 3 (12.0) 5 (33.3) 8 (33.3) 1 (12.5)
 N370S/L444P 24 (18.1) 8 (13.1) 7 (28.0) 5 (33.3) 2 (8.3) 2 (25.0)
 N370S/84GG 7 (5.3) 4 (6.6) 2 (8.0) 0 1 (4.2) 0
 N370S/IVS2+1 4 (3.0) 3 (4.9) 0 0 0 1 (12.5)
 N370S/other 31 (23.3) 9 (14.8) 10 (40.0) 4 (26.7) 7 (29.2) 1 (12.5)
 L444P/other 3 (2.2) 1 (1.6) 1 (4.0) 0 0 1 (12.5)
 L444P/L444P 1 (0.75) 0 1 (4.0) 0 0 0
 Other/other 5 (3.8) 1 (1.6) 1 (4.0) 1 (6.7) 0 2 (25.0)
 Unknown/missing 6 (4.5) 0 0 0 6 (25.0) 0
Baseline DS3 score*
 Mean (SD) 5.6 (2.6) 5.6 (2.5) 6.6 (2.9) 4.4 (2.3) 4.8 (2.4) 7.2 (2.0)

*Two-tailed t-test: Toronto v Atlanta: P=0.016; Toronto v California: P=0.020; Pittsburgh v Atlanta: P=0.008; Pittsburgh v California: P=0.016